2R3 Relative Valuation - Reata Pharmaceuticals Inc

Watchlist Manager

Watchlist

Price: 161 EUR Market Closed

Market Cap: €6B

R	Reata Pharmaceuticals Inc F:2R3	US

Multiples-Based Value

There is not enough data to reliably calculate the multiples-based value of 2R3.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is Relative Valuation?

How is Multiples-Based Value calculated?

2R3 Multiples-Based Value

Base Case

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
US	R	Reata Pharmaceuticals Inc F:2R3	6.1B EUR	305.6	-81.9	-20.3	-20.3
US		Eli Lilly and Co NYSE:LLY	847.5B USD	12.8	40.3	27.3	29.1
US		Johnson & Johnson NYSE:JNJ	576.1B USD	6.1	21.6	15	18.4
CH		Roche Holding AG SIX:ROG	248.4B CHF	4	19.3	11.5	12.9
US		Merck & Co Inc NYSE:MRK	294.3B USD	4.6	16.2	10	12.2
CH		Novartis AG SIX:NOVN	229.3B CHF	5.2	21.1	13	16.8
UK		AstraZeneca PLC LSE:AZN	214.5B GBP	5.1	29.1	16.1	22.7
IE	E	Endo International PLC LSE:0Y5F	237.1B USD	102.3	-81.1	375.3	941.3
DK		Novo Nordisk A/S CSE:NOVO B	1T DKK	3.3	9.8	7.3	8.6
US		Pfizer Inc NYSE:PFE	156.8B USD	2.5	19.8	7.6	10.2
US		Bristol-Myers Squibb Co NYSE:BMY	119.6B USD	2.4	16.7	7.1	8.7

				Revenue Growth	P/S to Growth
US	R	Reata Pharmaceuticals Inc F:2R3	Average P/S: 41.3 305.6	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	12.8	19%	0.7
US		Johnson & Johnson NYSE:JNJ	6.1	6%	1
CH		Roche Holding AG SIX:ROG	4	4%	1
US		Merck & Co Inc NYSE:MRK	4.6	5%	0.9
CH		Novartis AG SIX:NOVN	5.2	5%	1
UK		AstraZeneca PLC LSE:AZN	5.1	7%	0.7
IE	E	Endo International PLC LSE:0Y5F	102.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	3.3	2%	1.6
US		Pfizer Inc NYSE:PFE	2.5	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.4	-5%	N/A

				Earnings Growth	PEG
US	R	Reata Pharmaceuticals Inc F:2R3	Average P/E: 21.6 Negative Multiple: -81.9	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	40.3	32%	1.3
US		Johnson & Johnson NYSE:JNJ	21.6	7%	3.1
CH		Roche Holding AG SIX:ROG	19.3	14%	1.4
US		Merck & Co Inc NYSE:MRK	16.2	14%	1.2
CH		Novartis AG SIX:NOVN	21.1	14%	1.5
UK		AstraZeneca PLC LSE:AZN	29.1	26%	1.1
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -81.1	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	9.8	1%	9.8
US		Pfizer Inc NYSE:PFE	19.8	22%	0.9
US		Bristol-Myers Squibb Co NYSE:BMY	16.7	16%	1

				EBITDA Growth	EV/EBITDA to Growth
US	R	Reata Pharmaceuticals Inc F:2R3	Average EV/EBITDA: 49 Negative Multiple: -20.3	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	27.3	22%	1.2
US		Johnson & Johnson NYSE:JNJ	15	2%	7.5
CH		Roche Holding AG SIX:ROG	11.5	6%	1.9
US		Merck & Co Inc NYSE:MRK	10	3%	3.3
CH		Novartis AG SIX:NOVN	13	5%	2.6
UK		AstraZeneca PLC LSE:AZN	16.1	13%	1.2
IE	E	Endo International PLC LSE:0Y5F	375.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	7.3	1%	7.3
US		Pfizer Inc NYSE:PFE	7.6	-9%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	7.1	-10%	N/A

				EBIT Growth	EV/EBIT to Growth
US	R	Reata Pharmaceuticals Inc F:2R3	Average EV/EBIT: 108.1 Negative Multiple: -20.3	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	29.1	22%	1.3
US		Johnson & Johnson NYSE:JNJ	18.4	6%	3.1
CH		Roche Holding AG SIX:ROG	12.9	6%	2.2
US		Merck & Co Inc NYSE:MRK	12.2	6%	2
CH		Novartis AG SIX:NOVN	16.8	9%	1.9
UK		AstraZeneca PLC LSE:AZN	22.7	21%	1.1
IE	E	Endo International PLC LSE:0Y5F	941.3	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	8.6	2%	4.3
US		Pfizer Inc NYSE:PFE	10.2	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	8.7	-7%	N/A

Reata Pharmaceuticals Inc
F:2R3

Multiples-Based Value

Valuation Multiples

Multiples Across Competitors

2R3 Competitors Multiples
Reata Pharmaceuticals Inc Competitors

See Also

Company

Help

Tools

Stocks

Reata Pharmaceuticals Inc F:2R3

Multiples-Based Value

Valuation Multiples

Multiples Across Competitors

2R3 Competitors Multiples Reata Pharmaceuticals Inc Competitors

See Also

Company

Help

Tools

Stocks

Reata Pharmaceuticals Inc
F:2R3

2R3 Competitors Multiples
Reata Pharmaceuticals Inc Competitors